A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.

Breast Cancer · 2019 · PMC6821663 · PMID 31079343

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the second-line setting, there was a trend to improvement; while this did not reach statistical significance, the test for heterogeneity indicates that there was no evidence that the treatment effects were not consistent across the first- and second-line studies.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.